NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free PCVX Stock Alerts $60.06 -0.24 (-0.40%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$58.10▼$60.0950-Day Range$60.30▼$81.0552-Week Range$41.57▼$82.04Volume1.57 million shsAverage Volume842,040 shsMarket Capitalization$6.53 billionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaxcyte alerts: Email Address Vaxcyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.7% Upside$78.50 Price TargetShort InterestBearish7.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 8 Articles This WeekInsider TradingSelling Shares$6.47 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.18) to ($4.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.99 out of 5 starsMedical Sector562nd out of 907 stocksBiological Products, Except Diagnostic Industry93rd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.58% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Vaxcyte has recently decreased by 0.24%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 2.6 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Vaxcyte this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,471,835.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.18) to ($4.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -14.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -14.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Vaxcyte Stock (NASDAQ:PCVX)Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesApril 23, 2024 | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockMarch 28, 2024 | insidertrades.comGrant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 24, 2024 | finance.yahoo.comVaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | investing.comVaxcyte president and CFO sells shares worth over $490kApril 21, 2024 | finance.yahoo.comVaxcyte, Inc. (PCVX)April 14, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - PCVXApril 10, 2024 | msn.comVaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst SaysApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 2, 2024 | globenewswire.comVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | finance.yahoo.comInsider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 SharesMarch 16, 2024 | ca.finance.yahoo.comPCVX Jul 2024 70.000 putMarch 16, 2024 | ca.finance.yahoo.comPCVX Apr 2024 80.000 putMarch 16, 2024 | finance.yahoo.comPCVX Apr 2024 100.000 callMarch 12, 2024 | msn.comOracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For TuesdayMarch 4, 2024 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 4, 2024 | globenewswire.comVaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte Amid Anticipation of Transformative VAX-31 Data ReleaseMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte on Strong Vaccine Candidate Prospects and Upward Financial ProjectionsFebruary 28, 2024 | markets.businessinsider.comVaxcyte’s VAX-31 Poised for Market Leadership: Shrader’s Bullish Forecast and Price Target UpdateFebruary 28, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Vaxcyte (PCVX)February 28, 2024 | finance.yahoo.comVaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | seekingalpha.comVaxcyte, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | globenewswire.comVaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 26, 2024 | benzinga.comVaxcyte Stock (NASDAQ:PCVX), Short Interest ReportFebruary 25, 2024 | insidermonkey.com5 Best Russell 2000 Stocks To Buy According To Hedge FundsFebruary 17, 2024 | finance.yahoo.comPCVX Apr 2024 50.000 callSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees254Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$69.00 Potential Upside/Downside+31.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.04% Return on Assets-29.72% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book4.56Miscellaneous Outstanding Shares108,760,000Free Float104,844,000Market Cap$6.47 billion OptionableOptionable Beta0.89 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 56)Co-Founder, CEO & Director Comp: $1.1MMr. Andrew L. Guggenhime M.B.A. (Age 56)President & CFO Comp: $839.65kMr. James Wassil M.B.A. (Age 55)M.S., Executive VP & COO Comp: $826.3kMr. Paul W. Sauer M.B.A. (Age 63)Senior Vice President of Process Development & Manufacturing Comp: $608.96kDr. Ashish Khanna M.B.A. (Age 52)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 60)Co-Founder & VP of Research Ms. Elvia Cowan (Age 51)Senior VP of Finance & Principal Accounting Officer Ms. Janet GraesserSenior Vice President of Corporate Communications & Investor RelationsMs. Whitney JonesChief People OfficerMr. Harp Dhaliwal M.B.A. (Age 51)Senior Vice President of Commercial Manufacturing & Supply Chain Comp: $146.48kMore ExecutivesKey CompetitorsExelixisNASDAQ:EXELRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsRaymond James & AssociatesBought 14,779 shares on 4/22/2024Ownership: 0.061%Andrew GuggenhimeSold 8,000 sharesTotal: $490,160.00 ($61.27/share)Allspring Global Investments Holdings LLCBought 24,785 shares on 4/18/2024Ownership: 0.044%Banque Cantonale VaudoiseBought 582 shares on 4/10/2024Ownership: 0.001%Grant PickeringSold 15,000 sharesTotal: $1.00 M ($66.93/share)View All Insider TransactionsView All Institutional Transactions PCVX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxcyte stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks. What is Vaxcyte's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price objectives for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they anticipate the company's share price to reach $78.50 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts. How have PCVX shares performed in 2024? Vaxcyte's stock was trading at $62.80 at the beginning of 2024. Since then, PCVX shares have decreased by 4.4% and is now trading at $60.06. View the best growth stocks for 2024 here. When is Vaxcyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PCVX earnings forecast. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same period in the previous year, the firm posted ($0.73) EPS. What ETFs hold Vaxcyte's stock? ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Amplify Treatments, Testing and Advancements ETF (GERM), Alger Mid Cap 40 ETF (FRTY), Harbor Health Care ETF (MEDI), Principal Healthcare Innovators ETF (BTEC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Fidelity Disruptive Medicine ETF (FMED) and SPDR S&P Biotech ETF (XBI). What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP). When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's stock is owned by many different retail and institutional investors. Top institutional investors include Raymond James & Associates (0.06%), Allspring Global Investments Holdings LLC (0.04%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Andrew Guggenhime, Elvia Cowan, Grant Pickering, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman and Paul Sauer. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCVX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
